Pharmacokinetic and Pharmacodynamic Study of Lenograstim for Hematopoietic Stem Cell Mobilization
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Twenty four patients with multiple myeloma will be randomized to either AM group
(administration of lenograstim at 8 am) or PM group (administration of lenograstim at 6 am ).
Apheresis of hematopoietic stem cell will start at 10 am on D5 in AM group and at 8 am on D4
in PM group, respectively. Pharmacokinetic data of lenograstim will be correlated with
pharmacodynamic data of CD34+ cell count, absolute neutrophil cell count and hematopoeitic
progenitor cell count. In addition, the yield of stem cell collection between two arms will
be analyzed.